Enzo Biochem, Inc. (NYSE:ENZ) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Monday.

Separately, Zacks Investment Research cut Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th.

Shares of Enzo Biochem (NYSE ENZ) opened at 11.06 on Monday. The firm has a 50 day moving average price of $11.28 and a 200-day moving average price of $8.94. Enzo Biochem has a 12 month low of $4.88 and a 12 month high of $12.04. The firm has a market cap of $513.26 million, a PE ratio of 15.51 and a beta of 0.97.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/14/enzo-biochem-inc-nyseenz-downgraded-to-sell-at-bidaskclub.html.

A number of institutional investors have recently bought and sold shares of the company. Prudential Financial Inc. bought a new stake in shares of Enzo Biochem during the first quarter valued at about $149,000. Bank of New York Mellon Corp increased its stake in shares of Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock valued at $1,728,000 after buying an additional 2,409 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Enzo Biochem by 17.9% in the first quarter. TIAA CREF Investment Management LLC now owns 371,069 shares of the medical research company’s stock valued at $3,106,000 after buying an additional 56,301 shares during the period. State Street Corp increased its stake in shares of Enzo Biochem by 7.3% in the fourth quarter. State Street Corp now owns 567,070 shares of the medical research company’s stock valued at $3,931,000 after buying an additional 38,672 shares during the period. Finally, Trexquant Investment LP bought a new stake in shares of Enzo Biochem during the first quarter valued at about $115,000. Institutional investors and hedge funds own 62.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.